Compositions and methods for inhibiting CD279 interactions
AssigneeVirogin Biotech Canada Ltd
InventorsWilliam Jia, Xuexian Bu, I-Fang Lee
Life of this patent
Estimating the term…
Abstract
Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.
Claims10
A method for inhibiting an interaction between programmed death-1 protein (PD-1) and programmed death-ligand 1 (PD-L1) in a cell by administering one or more peptides to the cell, wherein each of said peptides consists of one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-SEQ ID NO:36.
A method for treating breast cancer, lung cancer, melanoma, or renal cancer in a subject by administering one or more peptides to the subject, wherein each of said peptides consists of one or more of the amino acid sequences that are selected from the group consisting of SEQ ID NO:1-SEQ ID NO:36.
Dependencies are inferred from the claim text.